PDCD1 and non-small cell lung carcinoma: To the best of our knowledge, the INCREASE study is the first to investigate the safety and efficacy of adding dual immunotherapy, using a PD-1 and a CTLA-4 blocker, to high-dose concurrent CRT in the neoadjuvant setting for locally advanced NSCLC.